Pulmonary fibrosis is a refractory disease and there is no curative drug available. The following classes of drugs are used clinically to delay and improve the degree of pulmonary fibrosis, improve the quality of survival and prolong the survival period of patients. Commonly used anti-fibrotic drugs include: first, pirfenidone and nidanib, which are the main anti-fibrotic drugs strongly recommended by relevant guidelines and have been widely used in clinical practice, and their safety and efficacy have been confirmed. Second, antioxidants such as acetylcysteine effervescent tablets and carboxymesterol tablets, which are used by combining anti-fibrotic drugs together. Third, glucocorticoids and immunosuppressive modulators such as methylprednisolone tablets, prednisone tablets, methotrexate, cyclophosphamide, etc. However, these drugs are mainly used for pulmonary fibrosis caused by certain causes. For the treatment of pulmonary fibrosis, early detection and early drug treatment are required, and it is important to visit a specialist hospital and follow the principle of individualization in order to improve the prognosis of patients.